A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis

Inclusion Criteria: * Patients who completed the parent trial 1199.214/1199-0340 per protocol and did not permanently discontinue study treatment * Signed and dated written informed consent in accordance with International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial * Women of childbearing potential must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly as well as one barrier method for 28 days prior to nintedanib treatment initiation, during the trial and for 3 months after last intake of nintedanib. * Further inclusion criteria apply Exclusion Criteria: * Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) \> 3 x Upper Limit of Normal (ULN) * Bilirubin \> 2 x ULN * Creatinine clearance \<30 mL/min calculated by Cockcroft-Gault formula. * Clinically relevant anaemia at investigators discretion. * Bleeding risk, any of the following * Known genetic predisposition to bleeding according to the judgement of the investigator * Patients who require * Fibrinolysis, full-dose therapeutic anticoagulation * High dose antiplatelet therapy. * Hemorrhagic central nervous system (CNS) event after completion of the parent trial 1199.214/1199-0340 * Any of the following after last treatment of 1199.214/1199-0340: * Haemoptysis or haematuria * Active …